Home » Teva Alleges Further Infringement Against Copaxone Patents
Teva Alleges Further Infringement Against Copaxone Patents
Teva Pharmaceutical Industries is seeking
to add infringement of three additional patents on its multiple sclerosis drug Copaxone to its claims against Momenta Pharmaceuticals and Sandoz. The amended
complaint seeks to include additional patents related to the characterization of Copaxone’s active
ingredient, Teva says in a statement this week.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May